GENFF
Price
$0.01
Change
-$0.00 (-0.00%)
Updated
Jul 2 closing price
Capitalization
4.52M
OCS
Price
$19.00
Change
-$0.16 (-0.84%)
Updated
Jul 3 closing price
Capitalization
969.64M
Interact to see
Advertisement

GENFF vs OCS

Header iconGENFF vs OCS Comparison
Open Charts GENFF vs OCSBanner chart's image
Genflow Biosciences
Price$0.01
Change-$0.00 (-0.00%)
Volume$70K
Capitalization4.52M
Oculis Holding AG
Price$19.00
Change-$0.16 (-0.84%)
Volume$8.55K
Capitalization969.64M
GENFF vs OCS Comparison Chart in %
Loading...
GENFF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OCS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GENFF vs. OCS commentary
Jul 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GENFF is a Hold and OCS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 04, 2025
Stock price -- (GENFF: $0.01 vs. OCS: $19.00)
Brand notoriety: GENFF and OCS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GENFF: 955% vs. OCS: 30%
Market capitalization -- GENFF: $4.52M vs. OCS: $969.64M
GENFF [@Biotechnology] is valued at $4.52M. OCS’s [@Biotechnology] market capitalization is $969.64M. The market cap for tickers in the [@Biotechnology] industry ranges from $310.37B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GENFF’s FA Score shows that 0 FA rating(s) are green whileOCS’s FA Score has 0 green FA rating(s).

  • GENFF’s FA Score: 0 green, 5 red.
  • OCS’s FA Score: 0 green, 5 red.
According to our system of comparison, OCS is a better buy in the long-term than GENFF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GENFF’s TA Score shows that 2 TA indicator(s) are bullish while OCS’s TA Score has 3 bullish TA indicator(s).

  • GENFF’s TA Score: 2 bullish, 4 bearish.
  • OCS’s TA Score: 3 bullish, 3 bearish.
According to our system of comparison, OCS is a better buy in the short-term than GENFF.

Price Growth

GENFF (@Biotechnology) experienced а -1.75% price change this week, while OCS (@Biotechnology) price change was -2.46% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.93%. For the same industry, the average monthly price growth was +17.38%, and the average quarterly price growth was -0.11%.

Reported Earning Dates

OCS is expected to report earnings on May 08, 2025.

Industries' Descriptions

@Biotechnology (+6.93% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
OCS($970M) has a higher market cap than GENFF($4.52M). OCS YTD gains are higher at: 11.765 vs. GENFF (-81.426).
GENFFOCSGENFF / OCS
Capitalization4.52M970M0%
EBITDAN/A-101.78M-
Gain YTD-81.42611.765-692%
P/E RatioN/A63.08-
RevenueN/A0-
Total CashN/A182M-
Total DebtN/A1.1M-
TECHNICAL ANALYSIS
Technical Analysis
GENFFOCS
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
50%
Bullish Trend 1 day ago
49%
Momentum
ODDS (%)
Bearish Trend 1 day ago
63%
Bearish Trend 1 day ago
34%
MACD
ODDS (%)
Bearish Trend 1 day ago
33%
Bearish Trend 1 day ago
44%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
54%
Bearish Trend 1 day ago
48%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
46%
Bearish Trend 1 day ago
48%
Advances
ODDS (%)
N/A
Bullish Trend 10 days ago
73%
Declines
ODDS (%)
N/A
Bearish Trend 14 days ago
63%
BollingerBands
ODDS (%)
N/A
N/A
Aroon
ODDS (%)
Bullish Trend 1 day ago
36%
Bullish Trend 1 day ago
56%
View a ticker or compare two or three
Interact to see
Advertisement
GENFF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OCS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ASCGX20.250.28
+1.40%
Lisanti Small Cap Growth
MYSPX66.930.56
+0.84%
NYLI S&P 500 Index Investor Class
NYVCX20.240.11
+0.55%
Davis NY Venture C
HSMYX13.05N/A
N/A
Hartford Small Cap Value Y
BUITX24.20N/A
N/A
Buffalo Mid Cap Discovery Inst

GENFF and

Correlation & Price change

A.I.dvisor tells us that GENFF and TOVX have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that GENFF and TOVX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GENFF
1D Price
Change %
GENFF100%
N/A
TOVX - GENFF
25%
Poorly correlated
-1.56%
VRCA - GENFF
23%
Poorly correlated
+9.01%
SGMT - GENFF
10%
Poorly correlated
+1.73%
OCS - GENFF
6%
Poorly correlated
-0.81%
APGE - GENFF
3%
Poorly correlated
+7.08%
More

OCS and

Correlation & Price change

A.I.dvisor indicates that over the last year, OCS has been loosely correlated with SNSE. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if OCS jumps, then SNSE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OCS
1D Price
Change %
OCS100%
-0.81%
SNSE - OCS
34%
Loosely correlated
-2.54%
CUE - OCS
33%
Poorly correlated
+0.46%
PRAX - OCS
29%
Poorly correlated
+2.03%
GRI - OCS
29%
Poorly correlated
-0.69%
CGEN - OCS
28%
Poorly correlated
+1.15%
More